Image
 

Locate Available Clinical Trials

To view available Clinical Trial information choose from the list on the right or search using the fields below.

 

 

trial #
trial description
  • Alliance A071601
  • The purpose of this study is to test any good and bad effects of the study drugs called vemurafenib and cobimetinib. Researchers have looked at the genes that can be affected in craniopharyngiomas and have found mutations or changes in the gene called BRAF.  When BRAF is altered, it can cause a tumor to grow.

    Vemurafenib and cobimetinib have already been FDA-approved to treat advanced melanoma. Unlike craniopharyngioma, melanoma is a malignant tumor, however, both melanoma and craniopharyngiomas may have mutations in the gene called BRAF.  Both drugs have not been tested in craniopharyngiomas. Because craniopharyngiomas have the same change in the BRAF gene as has been found in melanoma, the purpose of the study is to see if these drugs can shrink craniopharyngiomas. When needed, researchers will also look at a gene called beta-catenin for further confirmations in some cases.

  • Alliance A091302
  • The purpose of this study is to compare any good and bad effects of using everolimus along with sorafenib versus sorafenib alone. The addition of everolimus to the usual sorafenib might cause more shrinkage your cancer and might prevent it from growing but it could also cause more side effects than sorafenib alone. This study will allow the researchers to know whether this treatment with two drugs is better, the same or worse than the usual approach (which is sorafenib alone). To be better, the study drugs should increase the time it takes your cancer to progress by four and a half months or more compared to the usual approach.

  • Alliance A091305
  • The purpose of this study is to compare any good and bad effects of using efatutazone along with the usual chemotherapy to using the usual chemotherapy alone for patients with Anaplastic Thyroid Cancer.

  • NRG HN003
  • This study tests the timing of the dose of pembrolizumab paired with the timing of the radiation and chemotherapy to see which combination is safer in people. The purpose of this study is to test the safety and schedule of adding full-dose pembrolizumab to radiation therapy and cisplatin chemotherapy. 

  • NRG-HN001
  • This study is being done to see how people with nasopharyngeal cancer respond to different types or levels of chemotherapy, based on a specific viral marker in their blood. This viral marker is called the Epstein Barr virus, (EBV). A more individualized approach to treating your type of cancer might be found using this blood marker.

  • NRG/RTOG 0920
  • The purpose of this study is to compare the effects, good and/or bad, of radiation therapy alone with radiation therapy and cetuximab on head and neck cancer to find out which is better.

  • RTOG 1216
  • The purpose of this study is to compare the effects, good and/or bad, of two standard treatments for head and neck cancer: radiation therapy and cisplatin or radiation therapy and cetuximab. The two treatments may be comparable in treating your cancer, but radiation and cetuximab may result in less severe side effects. This study is being done in patients whose head and neck cancer was caused by Human Papillomavirus (HPV). Some studies have found that patients with HPV positive oropharynx cancer have a better response to treatment and live longer. Thus, this study aims to see if treatment with radiation plus cetuximab has less side effects and is as effective as radiation plus cisplatin.